Skip to main content
. Author manuscript; available in PMC: 2017 Aug 31.
Published in final edited form as: Br J Haematol. 2015 Jun 30;171(1):91–99. doi: 10.1111/bjh.13529

Figure 3.

Figure 3

TP53 expression and survival. Patients with myelodysplastic syndrome with fibrosis in the TP53high group had (A) a significantly shorter overall survival (OS) compared to patients in the TP53neg-low group (p=0.0096) and (B) tended to have a shorter leukaemia-free survival (p=0.058).